Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib

Alimentary Pharmacology and Therapeutics

Volumn 17, Issue 2, 2003, Pages 201-210

  Hunt, Richard H ^a   Harper, S ^b   Callegari, P ^b   Yu, C ^b   Quan, H ^b   Evans, J ^b   James, C ^a   Bowen, B ^a   Rashid, F ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATTAPULGITE; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; IBUPROFEN; NAPROXEN; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OCCULT BLOOD; OSTEOARTHRITIS; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STOMACH PROTECTION; STOMACH ULCER; THROMBOCYTE FUNCTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; DUODENAL ULCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; IBUPROFEN; ISOENZYMES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OCCULT BLOOD; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIDINES; STOMACH ULCER; SULFONES;

EID: 0037315063     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01407.x     Document Type: Article

References (50)

1. Fries JF. NSAID gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991; 18(Suppl. 28): 6-10.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5.
3. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats: prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. Gastroenterology 1979; 77: 433-43.
4. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Gastric cytoprotective property of prostaglandins [Abstract]. Gastroenterology 1977; 72(5): 1121.
5. Redfern JS, Feldman M. Role of endogenous prostaglandins in preventing gastrointestinal ulceration: induction of ulcers by antibodies to prostaglandins. Gastroenterology 1989; 96(2 Part 2): 596-605.
6. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9.
7. Ristimaki A, Honkanen N, Jankala H, Siponen P, Harkonen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 1997; 57: 1276-80.
8. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal antiinflammatory drugs. Am J Med 1998; 104: 413-21.
9. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal antiinflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114: 307-19.
10. Shorrock CJ, Rees WDW. Overview of gastroduodenal mucosal protection. Am J Med 1988; 84(Suppl. 2A): 25-34.
11. Cryer B. Nonsteroidal anti-inflammatory drugs and gastrointestinal disease. In: Feldman M. Scharschmidt BF, Sleisenger MG, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 6th edn. Philadelphia: W. B. Saunders. 1998; 343-57.
12. Hunt RH, Bowen B, Mortensen E. et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000; 109: 201-6.
13. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000; 43(2): 370-7.
14. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999; 117: 776-83.
15. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343(21): 1520-8.
16. Clemett D, Goa K. Celecoxib. A review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000; 59(4): 957-80.
17. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J Am Med Assoc 1999; 282: 1921-8.
18. Celecoxib: an NSAD with improved gastrointestinal tolerability. Drug Ther Perspect 2001; 17(5): 1-5.
19. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis (the CLASS study): a randomized controlled trial. J Am Med Assoc 2000; 284: 1247-55.
20. Langman M, Jensen D, Watson D, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J Am Med Assoc 1999; 282(20): 1929-33.
21. 51Cr technique to detect gastrointestinal microbleeding associated with nonsteroidal antiinflammatory drugs. Semin Arthritis Rheum 1988; 17(Suppl. 2): 40-5.
22. Ridolfo AS, Crabtree RE, Johnson DW, Rockhold FW. Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents. J Rheumatol 1980; (Suppl. 6): 36-46.
23. 51Cr-labelled erythrocytes. Scand J Rheumatol 1989; 18: 307-13.
24. Chernish SM, Rosenak BD, Brunelle RL, Crabtree R. Comparison of gastrointestinal effects of aspirin and fenoprofen. Arthritis Rheum 1979; 22(4): 376-83.
25. Lanza FL, Arnold JD. Etodolac. a new nonsteroidal antiinflammatory drug: gastrointestinal microbleeding and endoscopic studies. Clin Rheumatol 1989; 8(Suppl. 1): 5-15.
26. Loebl DH, Craig RM, Culic DD, Ridolfo AS, Falk J, Schmid FR. Gastrointestinal blood loss - effect of aspirin, fenoprofen, and acetaminophen in rheumatoid arthritis as determined by sequential gastroscopy and radioactive fecal markers. J Am Med Assoc 1977; 237(10): 976-81.
27. Ryan JR, Vargas R, Clay GA, McMahon FG. Role of misoprostol in reducing aspirin-induced gastrointestinal blood loss in arthritic patients. Am J Med 1987; 83(Suppl. 1A): 41-4.
28. Silverstein FE. Improving the gastrointestinal safety of NSAIDs: the development of misoprostol - from hypothesis to clinical practice. Dig Dis Sci 1998; 43(3): 447-58.
29. Gottesdiener K, Schnitzer T, Fisher C, et al. MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee [Abstract]. Arthritis Rheum 2000; 42(Suppl. 9): S144.
30. Malmstrom K, Shahane A, Fricke JR, Ehrich E. MK-0663, a new COX-2 inhibitor: the effect in acute pain using the dental-impaction model [Abstract]. Arthritis Rheum 2000; 43(Suppl. 9): S299.
31. Griffin MR, Piper JM. Daugherty JR, Snowden M, Ray WA. Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114(4): 257-63.
32. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991; 115(10): 787-96.
33. Taha AS, Sturrock RD, Russell RI. Mucosal erosions in long-term nonsteroidal antiinflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori. Gut 1995; 36: 334-6.
34. Breslow EN, Crowley J. A large sample study of the life table and product limit estimates under random censorship. Ann Stat 1974; 2: 437-53.
35. Harper S, Lee M, Curtis S, Ng J, Watson D, Bolognese J. A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs). Arthritis Rheum 2001; 44(9 Suppl.): S318.
36. Lussier A, LeBel E. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone. Am J Med 1987; 83(Suppl. 4B): 15-8.
37. Fosslein E. Adverse effects of nonsteroidal antiinflammatory drugs on the gastrointestinal system. Clin Lab Sci 1998; 28(2): 67-81.
38. Jain K. Evaluation of intravenous parecoxib for the relief of acute post-surgical pain. Exp Opin Invest Drugs 2000; 9(11): 2717-23.
39. Dallob A, Depré M, De Lepeleire I, et al. MK-0663. A highly specific inhibitor of COX-2 in humans. Ann Rheum Dis 2000; 59(Suppl. 1): 331.
40. Wight N, Gottesdiener K, Wong P, Calder N, Cote J, Hawkey C. Sparing of gastric mucosal prostaglandin synthesis in humans by etoricoxib [Abstract]. Gut 2001; 49(Suppl. III): Abstract 2865.
41. Shigeta J, Takahashi S, Ishikawa M, Okabe S. Role of cyclooxygenase-2 (COX-2) in the healing of gastric ulcers in rats [Abstract]. Gastroenterology 1998; 114: A285 (Abstract).
42. Schmassmann A, Peskar BM, Stettler C, et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastro-intestinal ulcer models in rats. Br J Pharmacol 1998; 123: 795-804.
43. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997; 112(2): 387-97.
44. Tatsuguchi A, Sakamoto C, Wada K, et al. Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans. Gut 2000; 46: 782-9.
45. Hudson N, Balsitis M, Everitt S, Hawkey CJ. Angiogenesis in gastric ulcers: impaired in patients taking non-steroidal antiinflammatory drugs. Gut 1995; 37: 191-4.
46. Szabo S. Mechanisms of gastric mucosal injury and protection. J Clin Gastroenterol 1991; 13(Suppl. 2): S21-34.
47. Szabo S, Hollander D. Pathways of gastrointestinal protection and repair; mechanisms of action of sucralfate. Am J Med 1989; 86(6A): 23-31.
48. Riegler M, Fell W, Lindroth J, Wong M. MIPSY: Real time morphometry to quantify the time course of rapid epithelial restitution. Pathol Res Pract 1992; 188(4-5): 443-8.
49. Yeomans ND, Skeljo MV. Repair and healing of established gastric mucosal injury. J Clin Gastroenterol 1991; 13(Suppl.): S37-41.
50. Rubin E, Farber J. Pathology. Philadelphia: J. B. Lippincott. 1998.